Radiation therapy of Hodgkin's disease: Significance of splenic involvement

Cancer ◽  
1974 ◽  
Vol 34 (1) ◽  
pp. 223-229 ◽  
Author(s):  
William U. Shipley ◽  
Anthony J. Piro ◽  
Samuel Hellman
Keyword(s):  
Radiation Therapy ◽  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
Splenic Involvement

The effects of prior radiation therapy and age on the frequency and duration of complete remission among various four-drug treatments for advanced Hodgkin's disease.

1984 ◽  
Vol 2 (7) ◽  
pp. 748-755 ◽  
Author(s):  
M R Cooper ◽  
T F Pajak ◽  
A J Gottlieb ◽  
A S Glicksman ◽  
N Nissen ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Complete Remission ◽  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
Significant Risk ◽  
Complete Response ◽  
Response To Therapy ◽  
Prior Therapy ◽  
Splenic Involvement ◽  
Advanced Hodgkin’S Disease

The current report examines the clinical response observed in 137 patients with advanced Hodgkin's disease who had relapsed from an initial complete response following radiation therapy (RTF) in comparison to 280 patients with no prior therapy (NPT). Patients were prospectively randomized to therapy with a four-drug combination chemotherapy program to determine whether CCNU and/or vinblastine are more effective than mechlorethamine and/or vincristine when combined with procarbazine and prednisone. The frequency of complete remission (CR) was 75% for the RTF group compared to 60% of those with NPT (P = .005). In the RTF group, those patients receiving a nitrosourea (CCNU) had a significantly greater CR frequency than those receiving mechlorethamine (P = .006). Significant risk factors favoring longer duration of remission were age less than 40 (P = .005), the absence of splenic involvement (P = .007), and the use of CCNU-containing programs (P = .015). The advantage for CCNU-containing programs was seen only in patients less than 40 years of age. In this study, the strongest factors favorably affecting response to therapy were prior RTF, age less than 40 years, and treatment with a nitrosourea (CCNU).

Stage III Hodgkin's disease: improved survival with combined modality therapy as compared with radiation therapy alone.

1985 ◽  
Vol 3 (9) ◽  
pp. 1166-1173 ◽  
Author(s):  
P Mauch ◽  
T Goffman ◽  
D S Rosenthal ◽  
G P Canellos ◽  
S E Come ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
Combined Modality Therapy ◽  
Stage Iii ◽  
Stage Iiia ◽  
Combined Modality ◽  
Splenic Involvement ◽  
First Relapse ◽  
Survival Differences

This is a retrospective analysis of 120 patients with pathologically stage IIIA and IIIB Hodgkin's disease treated from April 1969 to December 1982. The median follow-up was 108 months. Treatment consisted of radiation therapy (RT) alone in 54 patients and combined radiation therapy and MOPP (nitrogen mustard, vincristine, procarbazine, prednisone) chemotherapy (CMT) in 66 patients. Stage III patients treated with CMT have an improved actuarial 12-year survival as compared with patients treated with RT alone with MOPP reserved for relapse (80% v 64%; P = .026). The 12-year actuarial freedom from first relapse by treatment for stage III patients is 83% and 40%, respectively (P less than .0001). Improved survivals following combined modality therapy are seen for the following subgroups of stage III patients: stage III2, 66% (CMT) v 44% (total nodal irradiation; TNI), P = .04; stage III1, 97% (CMT) v 73% (TNI), P = .05; stage III mixed cellularity or lymphocyte depletion histology, 94% (CMT) v 65% (TNI), P = .007; and stage III extensive splenic involvement, 77% (CMT) v 58% (TNI), P = .02. These survival differences are not seen in patients with nodular sclerosis or lymphocyte predominance histology or in patients with minimal splenic involvement. These data indicate that the initial use of CMT in stage III Hodgkin's disease results in an improved survival as compared with initial treatment with RT with MOPP reserved for relapse. Patients with limited Stage IIIA disease may still be candidates for radiation therapy alone.

Probability of carcinogenesis due to involved field and involved site radiation therapy techniques for supra- and infradiaphragmatic Hodgkin’s disease

2019 ◽  
Vol 57 ◽  
pp. 100-106 ◽  
Author(s):  
Kalliopi M. Kourinou ◽  
Michalis Mazonakis ◽  
Efrosini Lyraraki ◽  
Helen Α. Papadaki ◽  
John Damilakis
Keyword(s):  
Radiation Therapy ◽  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
Involved Field

Radiation therapy for early stage Hodgkin's disease: Australasian patterns of care

1995 ◽  
Vol 31 (2) ◽  
pp. 227-236 ◽  
Author(s):  
Michael Barton ◽  
John Boyages ◽  
Elizabeth Crennan ◽  
Sidney Davis ◽  
Richard J. Fisher ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Hodgkin's Disease ◽  
Early Stage ◽  
Hodgkin’S Disease ◽  
Patterns Of Care

scholarly journals Involved field radiation therapy for early stage Hodgkin's disease in children.Preliminary results

Cancer ◽  
1976 ◽  
Vol 37 (4) ◽  
pp. 1625-1632 ◽  
Author(s):  
William C. Cham ◽  
Charlotte T. C. Tan ◽  
Alvaro Martinez ◽  
Philip R. Exelby ◽  
Melvin Tefft ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Hodgkin's Disease ◽  
Early Stage ◽  
Hodgkin’S Disease ◽  
Field Radiation ◽  
Involved Field

Reduction of fatal complications from combined modality therapy in Hodgkin's disease.

1985 ◽  
Vol 3 (4) ◽  
pp. 501-505 ◽  
Author(s):  
P M Mauch ◽  
G P Canellos ◽  
D S Rosenthal ◽  
S Hellman
Keyword(s):  
Radiation Therapy ◽  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
Combined Modality Therapy ◽  
Low Risk ◽  
Acute Nonlymphocytic Leukemia ◽  
Maintenance Chemotherapy ◽  
Fatal Complication ◽  
Actuarial Risk ◽  
Fatal Complications

A total of 464 pathologically staged IA through IIIB Hodgkin's disease patients were evaluated for the risk of developing acute nonlymphocytic leukemia, non-Hodgkin's lymphoma, or a fatal infection after treatment with radiation therapy (RT) alone, initial combined radiation therapy and chemotherapy (CMT), or RT with MOPP administered at relapse. Patients received a standard six cycles of MOPP, and additional maintenance chemotherapy was not administered. Patients receiving total nodal irradiation (TNI) and MOPP chemotherapy have an 11.9% actuarial risk of developing a fatal complication at ten years, as compared to a 0.8% risk for lesser field irradiation and MOPP (P = .005). The risk with RT alone is 0.6%. Patients 40 years of age or older have a greater risk for complications. These data report a low risk for fatal complication with CMT when less than TNI is administered and when maintenance chemotherapy is not used.

Sign in / Sign up

Export Citation Format

Share Document